Veru Inc. Earnings Call Highlights Clinical Momentum

Veru Inc ((VERU)) has held its Q2 earnings call. Read on for the main highlights of the call.

Veru Inc.’s latest earnings call struck a cautiously optimistic tone as management balanced significant clinical advances with ongoing financial and regulatory challenges. Investors heard about strong functional data for its lead obesity-related drug, tighter cost controls and a bolstered cash position, but also lingering unprofitability, competitive pressures and a funding runway tied to upcoming trial milestones.

Enobosarm shows promising functional benefits with GLP‑1s

Veru spotlighted its Phase IIb “quality” study, where enobosarm combined with semaglutide preserved muscle function versus semaglutide alone. The 3 mg dose cut the share of patients with at least a 10% decline in stair‑climb power by 59.8% versus placebo plus semaglutide (p=0.0006), while the 6 mg dose delivered a 44.1% reduction with a p‑value just above conventional significance.

New Phase IIb ‘plateau’ trial underway and enrolling well

The company has launched its pivotal‑style Phase IIb “plateau” study in roughly 200 older, high‑BMI patients, with the first subject enrolled on March 9, 2026. Management reported that enrollment is tracking ahead of expectations, setting up an interim readout at 36 weeks and a primary 68‑week endpoint focused on body‑weight change.

Regulatory strategy built around weight loss and function

Executives outlined a flexible regulatory roadmap that hinges on incremental weight loss of at least 5% to anchor a Phase III efficacy claim. If that threshold is not met, Veru plans to lean on functional measures like stair‑climb performance and bone mineral density to seek approval, with current trials structured to preserve multiple potential pathways.

Obesity and sarcopenia create vast target market

Management underscored the scale of the opportunity, citing more than 1 billion people with obesity worldwide and roughly 2.5 billion overweight or obese adults. In the U.S., the company estimates about 30 million adults suffer from obesity with low muscle mass, including roughly 20 million older Medicare Part D patients who could fit the profile targeted by enobosarm.

R&D and SG&A expenses show meaningful declines

Veru continued to dial back spending, with R&D falling to $3.1 million from $3.9 million sequentially and nearly halving year‑to‑date versus the prior period. SG&A also moved lower, down to $4.1 million from $5.2 million quarter‑over‑quarter and reduced year‑to‑date, helped by lower stock compensation and winding down of the earlier Phase IIb study.

Cash balance and working capital strengthen runway

The company exited March 31, 2026 with $27.6 million in cash and restricted cash, up sharply from $15.8 million at the prior fiscal year‑end. Net working capital more than doubled to $28 million, supported by roughly $23.4 million in net proceeds from an autumn equity offering, which management believes is enough to get past the key Phase IIb interim.

Operating cash burn and net loss trend in the right direction

Cash used in operations over the first six months of the fiscal year dropped to $15.1 million from $19.1 million, signaling tighter spending discipline. Quarterly net loss from continuing operations improved to $3.1 million, or $0.13 per diluted share, versus $7.9 million or $0.54 a year earlier, marking a notable but still incomplete march toward breakeven.

Unprofitability and funding needs still hang over the story

Despite recent progress, Veru remains loss‑making with a history of negative operating cash flows and no commercial revenue base. Management acknowledged that completing full pivotal development will likely require additional capital beyond the current runway, leaving future financing dependent on clinical and regulatory execution.

Runway tied to a single inflection point in 2027

The company’s liquidity guidance hinges largely on reaching the 36‑week interim analysis for the plateau study, with cash expected to fund operations only slightly beyond that point. That concentration of risk around one trial milestone raises stakes for the interim data, which could determine both partnering options and the ease of raising follow‑on capital.

Label and regulatory complexity may slow progress

Veru cautioned that if weight‑loss benefits on top of GLP‑1s fall short, regulators may demand additional functional or bone‑density evidence, complicating Phase III design. The likelihood that labels must reference specific GLP‑1 partners could also force agent‑by‑agent studies, extending timelines and adding cost relative to a more straightforward obesity program.

Facing heavyweight competition from Lilly and Novo Nordisk

The company is pursuing a niche within an obesity market currently dominated by much larger pharmaceutical rivals, including Lilly and Novo Nordisk. Management recognized that rapidly evolving injectable and oral therapies may require enobosarm to be studied alongside multiple GLP‑1 products to remain commercially relevant.

Dose response questions after mixed statistical outcomes

While the 3 mg dose delivered highly significant preservation of stair‑climb power, the 6 mg arm missed the traditional p<0.05 cutoff by a narrow margin. That mixed picture leaves some uncertainty about the optimal dose selection and may prompt closer scrutiny from investors and regulators when future trial designs are finalized.

GAAP results aided by nonrecurring investment and asset gains

Management noted that improvements in reported earnings were helped by realized and fair‑value gains linked to legacy assets and securities. Since these items, including prior asset sales, are not expected to repeat, investors were reminded to focus more on core operating trends than on headline GAAP improvements.

Lower investing inflows underscore shift from asset sales

Cash from investing activities dropped to $2.5 million versus $18.4 million in the comparable prior‑year period, reflecting the absence of large asset‑sale proceeds. With fewer one‑time inflows to lean on, Veru’s near‑term financial flexibility increasingly depends on equity markets, partnerships and disciplined spending.

Guidance centers on Phase IIb plateau readout and cash runway

Looking ahead, Veru guided that the 68‑week plateau trial will use percent change in total body weight as its primary endpoint, with a 36‑week interim analysis focused on lean mass and fat mass changes expected in the first quarter of 2027. Management reiterated that current cash and working capital should carry the program through this interim, positioning the data as a key catalyst for future development and financing decisions.

Veru’s call left investors weighing attractive clinical signals and a clearly defined regulatory game plan against the realities of a small, loss‑making biotech in a fiercely competitive field. With cash now sufficient to reach a pivotal interim readout, the next phase of the enobosarm story will likely determine whether the company can convert early promise into durable shareholder value.